Business Context and Reporting Period
The filing is Aeglea BioTherapeutics, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2022, filed November 3, 2022. The request metadata identifies Spyre Therapeutics, Inc.; however, the supplied filing text identifies Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), so the company identity should be verified.
Aeglea was a clinical-stage biotechnology company developing engineered human enzyme therapeutics for rare metabolic diseases. Its principal programs were pegzilarginase for Arginase 1 Deficiency, pegtarviliase for Homocystinuria, and AGLE-325 for Cystinuria.
Financial Highlights
| Metric | Three Months Ended September 30, 2022 | Three Months Ended September 30, 2021 | Nine Months Ended September 30, 2022 | Nine Months Ended September 30, 2021 |
|---|---|---|---|---|
| Total revenue | $0.2 million | $1.4 million | $2.2 million | $15.1 million |
| Operating expenses | $18.9 million | $21.7 million | $67.8 million | $60.3 million |
| Loss from operations | $(18.8) million | $(20.3) million | $(65.6) million | $(45.2) million |
| Net loss | $(18.2) million | $(20.3) million | $(65.0) million | $(45.4) million |
| Basic and diluted loss per share | $(0.19) | $(0.31) | $(0.81) | $(0.69) |
| Cash used in operating activities | Not separately reported | Not separately reported | $(62.0) million | $(34.4) million |
Revenue consisted primarily of development-fee revenue under the Immedica license and supply agreement. No product revenue was generated. Nine-month 2021 revenue included $12.0 million of license revenue recognized upon transfer of the license; no comparable license revenue was recognized in 2022.
Research and development expense was $12.0 million in the third quarter and $44.3 million for the first nine months. General and administrative expense was $7.0 million in the third quarter and $23.5 million for the first nine months. The filing does not present a meaningful operating or net profit margin because the company remained loss-making; based on reported figures, nine-month operating and net margins were approximately negative 3,037% and negative 3,008%, respectively.
At September 30, 2022, cash and cash equivalents were $39.0 million, marketable securities were $34.7 million, and restricted cash was $1.5 million. Total cash, cash equivalents, marketable securities, and restricted cash were $75.2 million, with working capital of $64.5 million. Total liabilities were $24.0 million. The company reported no debt or credit facility, although it had operating and finance lease obligations.
Stockholders’ equity was $67.6 million, compared with $83.9 million at December 31, 2021. Common shares outstanding increased to 61.5 million from 49.4 million, principally reflecting the May 2022 equity financing and warrant exercises. An additional 32.7 million pre-funded warrants remained outstanding at September 30, 2022.
Material Changes Versus the Prior Comparable Period
- Third-quarter revenue decreased $1.2 million, or 88%, to $0.2 million, reflecting lower progress-based development revenue under the Immedica agreement.
- Nine-month revenue decreased $12.9 million, or 86%, primarily because the prior-year period included $12.0 million of license revenue.
- Third-quarter research and development expense decreased $2.9 million, or 19%, primarily due to lower PEACE Phase 3, pegtarviliase manufacturing, and corporate-related costs.
- Nine-month research and development expense increased $4.0 million, or 10%, driven by pegzilarginase BLA and launch activities, AGLE-325 IND-enabling work, and higher personnel costs.
- Nine-month general and administrative expense increased $3.4 million, or 17%, mainly from commercial development and personnel expenses.
- Nine-month net loss increased $19.6 million, or 43%, to $65.0 million.
- Operating cash burn increased $27.6 million, or 80%, to $62.0 million.
- In May 2022, the company raised approximately $42.9 million net through a registered direct offering of common stock and pre-funded warrants.
- In August 2022, the company announced a restructuring and headcount reduction. James Kastenmayer became Interim Chief Executive Officer and Michael Hanley became Chief Business Officer.
Guidance, Outlook, Risks, and Unusual Items
Management stated that existing cash, cash equivalents, and marketable securities were expected to fund operations into the fourth quarter of 2023. Despite that estimate, the company concluded that substantial doubt existed about its ability to continue as a going concern within twelve months after issuance of the financial statements because of recurring losses, expected future losses, and the need for additional capital.
- The company expected continued spending on pegzilarginase and pegtarviliase clinical development, potential commercialization preparation, and early AGLE-325 activities.
- The FDA issued a Refusal to File for the pegzilarginase BLA in June 2022, requesting additional effectiveness data and Chemistry, Manufacturing, and Controls information. The company continued discussions with the FDA regarding a path to resubmission.
- The FDA placed the U.S. pegtarviliase trial on partial clinical hold for enrollment of patients under age 18. The company believed adult U.S. enrollment and enrollment of eligible patients in the United Kingdom and Australia could continue.
- The EMA validated Immedica’s marketing authorization application for pegzilarginase in August 2022.
- AGLE-325 manufacturing, drug supply, and other activities were postponed pending raw materials and additional capital resources.
- COVID-19 continued to create risks involving patient enrollment, missed dosing, clinical-site operations, supply chains, manufacturing, and regulatory timelines.
- The company had no approved products or product revenue and expected to incur losses for the foreseeable future.
- The company had approximately $60.0 million of common stock remaining available under its at-the-market offering program, creating potential future dilution.
- Nasdaq notified the company that its stock price had remained below the $1.00 minimum bid requirement for 30 consecutive trading days. The initial compliance period was scheduled to expire January 16, 2023, subject to potential extension and other conditions.
- Management reported effective disclosure controls and procedures and no material changes in internal control over financial reporting during the quarter.
- Management stated that no material legal proceedings were pending.
Most Important Facts to Verify
- Confirm that this Aeglea BioTherapeutics filing, rather than a Spyre Therapeutics filing, is the intended source document.
- Verify the company’s ability to raise additional capital before the projected fourth-quarter 2023 funding horizon and monitor the going-concern disclosure.
- Track FDA feedback, additional evidence requirements, and the timing and feasibility of any pegzilarginase BLA resubmission.
- Monitor the pegtarviliase partial clinical hold, enrollment progress, safety data, and planned Phase 1/2 readout.
- Assess dilution from the 32.7 million outstanding pre-funded warrants and potential sales under the $60.0 million at-the-market program.
- Review the company’s Nasdaq bid-price compliance status and any reverse stock split or delisting-related actions.
- Reconcile the stated $75.2 million liquidity figure to cash, marketable securities, and restricted cash, and compare it with the $62.0 million nine-month operating cash burn.
- Evaluate Immedica-related milestones, royalties, deferred revenue, and the commercial implications of the FDA’s concerns about pegzilarginase effectiveness.